Latest Market Research Report 2025

  The global  inhaled nitric oxide delivery systems market  size is estimated to reach USD 434.2 million by 2028 registering a CAGR of 6.9%, according to a new report by Grand View Research, Inc. A rise in the cases of respiratory failure among neonates, increased pollution levels leading to lung diseases in adults, need for quick treatment response, and reduced complications are the factors driving the adoption of inhaled nitric oxide therapy. The presence of several small-scale manufacturers and research initiatives undertaken by major players to prove treatment efficacy against the SARS-CoV-2 virus further enhances market growth.   Safe and effective treatment regimen, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medications. This leads to the improved adoption of INO, potentially driving the market grow...

  Inhaled Nitric Oxide Delivery Systems Industry Overview The global inhaled nitric oxide delivery systems market size was valued at USD 247.5 million in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 6.9% from 2021 to 2028.    Inhaled Nitric Oxide (INO), a minimally invasive therapy, is proposed to treat conditions associated with reversible pulmonary vasoconstriction and pulmonary hypertension in children and adults. Improved safety and efficacy, a rapid offset of action, reduced toxicity, high concentration of drug at the target organ, avoidance of systemic adverse reaction, and reduced dose of medication are some of the advantages of INO over other medication. This is leading to the improved adoption of INO, potentially driving the market growth.   Gather more insights about the market drivers, restrains and growth of the Global Inhaled Nitric Oxide Delivery Systems Market   In vitro studies suggest that INO is effectiv...